# Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

> **NCT03660761** · PHASE2 · COMPLETED · sponsor: **Rongjie Tao** · enrollment: 25 (actual)

## Conditions studied

- Efficacy and Safety

## Interventions

- **DRUG:** apatinib
- **DRUG:** temodar

## Key facts

- **NCT ID:** NCT03660761
- **Lead sponsor:** Rongjie Tao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-03
- **Primary completion:** 2017-01-03
- **Final completion:** 2018-01-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03660761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03660761, "Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03660761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*